1. Schnabl B. PPAR agonists in primary biliary cholangitis. N Engl J Med. 2024;390(9):855–8.
2. You H, Duan W, Li S, et al. Guidelines on the diagnosis and management of primary biliary cholangitis (2021). J Clin Transl Hepatol. 2023;11(3):736–46.
3. Genfit. FDA and EMA grant Genfit’s elafibranor orphan drug designation for primary biliary cholangitis (PBC) [media release]. 29 Jul 2019. http://www.genfit.com.
4. Genfit. Genfit announces FDA grant of breakthrough therapy designation to elafibranor for the treatment of PBC [media release]. 18 Apr 2019. http://www.genfit.com.
5. Genfit. Genfit upates 2024 outlook following acceptance of elafibranor filings in primary biliary cholangitis (PBC) [media release]. 8 Dec 2023. http://www.genfit.com.